Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large M&A to spur growth, are getting a serious shake-up. From the FDA's shifting temperament and the ripple effects of the IRA, commercial disruptions, dealmaking ambiguities and…
Commercial analytics and forecasting underpin strategic decision-making and business planning across the pharmaceutical and life science sectors. Inaccurate risk…
Digital technologies have plenty to offer a pharma industry seeking to up its productivity game. Attention often focuses artificial intelligence powered drug discovery or…
After a 27-month rollercoaster ride, can we expect a return to normal? Battered biotech is reviving after booming and busting in spectacular fashion. M&A is…
Our annual World Preview infographic provides forward-looking analysis of the pharma and biotech market, based on Evaluate consensus forecasts to 2028. The top…
The European Society of Medical Oncology Conference (ESMO) in Paris has wrapped up and there was much to talk about as Europe’s top oncologists came together to announce…
Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. Huge demand for Covid…
Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. As the pandemic…
Once again, Evaluate Vantage provides the latest insights and expert perspectives on new developments in the PD-(L)1 inhibitor landscape. The last few months have been…
As we venture into the second half of 2022, has the medtech market hit its lowest ebb? Will the slump continue or are there a few flickers of light on the horizon, if you…
In a world awash with information, Evaluate is here to provide clarity with best-in-class data and expert insight. As we come to the end of a very rocky first…